Floatz logo

Kras Tcr-Transduced Pbl

Small Bowel Cancer

National Cancer Institute (NCI)Cell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Small Bowel Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
Cancer Research UK
Phase 2BB
FILGRASTIM
Cancer Research UK
Phase 2BB
VINCRISTINE SULFATE
Cancer Research UK
Phase 2BB
Inno-206
Cancer Research UK
Phase 2B

View all 50 →

Same molecule, other indications

Kras Tcr-Transduced Pbl is also rated in:

metastatic malignant neoplasmDormant
B
Indicative ·
59 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
digestive system carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →